327 related articles for article (PubMed ID: 11902815)
1. Progress in the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA
J Intern Med; 2001 Dec; 250(6):462-75. PubMed ID: 11902815
[TBL] [Abstract][Full Text] [Related]
2. Progress in human tumour immunology and immunotherapy.
Rosenberg SA
Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146
[TBL] [Abstract][Full Text] [Related]
3. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Rosenberg SA
Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S2-7. PubMed ID: 10685650
[No Abstract] [Full Text] [Related]
5. New opportunities for the development of cancer immunotherapies.
Rosenberg SA
Cancer J Sci Am; 1998 May; 4 Suppl 1():S1-4. PubMed ID: 9619263
[No Abstract] [Full Text] [Related]
6. The development of new cancer therapies based on the molecular identification of cancer regression antigens.
Rosenberg SA
Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458
[TBL] [Abstract][Full Text] [Related]
7. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
Tran E; Robbins PF; Rosenberg SA
Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Infiltrating Lymphocyte Therapy and Neoantigens.
Robbins PF
Cancer J; 2017; 23(2):138-143. PubMed ID: 28410302
[TBL] [Abstract][Full Text] [Related]
9. A new era of cancer immunotherapy: converting theory to performance.
Rosenberg SA
CA Cancer J Clin; 1999; 49(2):70-3, 65. PubMed ID: 11198888
[TBL] [Abstract][Full Text] [Related]
10. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and gene therapy of cancer.
Rosenberg SA
Cancer Res; 1991 Sep; 51(18 Suppl):5074s-5079s. PubMed ID: 1884383
[TBL] [Abstract][Full Text] [Related]
12. Immunology and immunotherapy of human cancer: present concepts and clinical developments.
Bremers AJ; Parmiani G
Crit Rev Oncol Hematol; 2000 Apr; 34(1):1-25. PubMed ID: 10781746
[TBL] [Abstract][Full Text] [Related]
13. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
Kim S; Haas GP; Hillman GG
Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
[TBL] [Abstract][Full Text] [Related]
14. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.
Rosenberg SA; Kawakami Y; Robbins PF; Wang R
Adv Cancer Res; 1996; 70():145-77. PubMed ID: 8902056
[No Abstract] [Full Text] [Related]
15. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
16. Modeling immunotherapy of the tumor-immune interaction.
Kirschner D; Panetta JC
J Math Biol; 1998 Sep; 37(3):235-52. PubMed ID: 9785481
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modeling of the effect of boosting tumor infiltrating lymphocyte in immunotherapy.
Kartono A; Subiyanto
Pak J Biol Sci; 2013 Oct; 16(20):1095-103. PubMed ID: 24506008
[TBL] [Abstract][Full Text] [Related]
19. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
Rosenberg SA
J Natl Cancer Inst; 1996 Nov; 88(22):1635-44. PubMed ID: 8931607
[TBL] [Abstract][Full Text] [Related]
20. Identification of tumor-regression antigens in melanoma.
Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
